We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Serious Infections Prevalent in ANCA-Associated Vasculitis

By LabMedica International staff writers
Posted on 08 Apr 2021
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are among the rheumatic diseases with the highest mortality and morbidity, due to their major multi-organ involvement (lungs, kidneys) and their relapsing nature requiring aggressive immunosuppressive treatment.

Serious infections (SI) are common in patients with ANCA-AAV) like granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Real-life data regarding their incidence and predisposing factors, after the introduction of B cell depleting agents, are limited while data quantifying the risk per treatment modality and year of the disease are missing.

Clinical Immunologists at the Hippokration General Hospital (Athens, Greece) and their colleagues conducted a multicenter, observational, retrospective study of patients with AAV followed in three referral centers in the Athens. The study included 162 patients with GPA (63%) and MPA (37%), males 51.9%, mean age 60.9 years, ΑΝCA+ 86%, and generalized disease 80%. During follow-up (891.2 patient-years, mean 5.4 years), 67 serious infections (SI) were recorded in 50 patients at an incidence rate of 7.5 /100 patient-years.

The team collected from each participant age, sex, date of diagnosis, diseases severity, disease activity at baseline (Birmingham Vasculitis Activity Score), ANCA serology, organ involvement, relapses, renal function [estimated glomerular filtration rate (eGFR) by CKD-EPI formula] during first induction of remission course) and treatment patterns (treatment types and duration for each treatment, both for induction and maintenance of remission as well as initial glucocorticoids (GC) dose at diagnosis). SI was defined those needing hospitalization or intravenous antibiotics as well as opportunistic infections. Given the high frequency of herpes zoster (HZ) in AAV population and the accompanying morbidity of this infection, all cases of HZ were considered as SI irrespective of hospitalization need.

The scientists found that the incidence of SI among patients undergoing induction treatment with cyclophosphamide was 19.34/100 patient-years compared with 11.34/100 for those whose induction regimen was with rituximab, for an incidence rate ratio for cyclophosphamide of 4.24. Patients with ANCA-associated vasculitides granulomatosis with polyangiitis and microscopic polyangiitis continued to have significant morbidity and mortality despite improvements in treatment, such as the wider use of rituximab, and the incidence of serious infections remained high.

Mean baseline estimated glomerular filtration rate (GFR) was 59.1 mL/min, and in almost a quarter of patients, the baseline GFR was below 30 mL/min. Renal replacement therapy and/or plasma exchange was needed at baseline for 6.2%. Site of infection was the respiratory tract in 45% of patients, and the gastrointestinal tract and urinary tract in 9% each. The infection was herpes zoster in 24% and bacteremia in 9%.

The authors concluded that in this real-life study of patients with AAV, the SI incidence was higher during cyclophosphamide compared to rituximab (RTX) induction while there was no difference between RTX and other agents used for maintenance therapy. Higher disease activity at baseline and need for plasmapheresis and/or dialysis were independent factors associated with an SI. The study was published on March 20, 2021 in the journal Arthritis Research & Therapy.

Related Links:
Hippokration General Hospital


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Lyme Disease Test
Lyme IgG/IgM Rapid Test Cassette
New
Centromere B Assay
Centromere B Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.